Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Table 3 Univariate and multivariate analyses of prognostic markers for PFS

	Univariate analysis (p-value)	Multivariate analysis (p-value)
Afatinib vs. erlotinib	0.97	ND
Age ≤70 years	0.008	0.006
Sex	0.79	ND
Smoking status	0.25	ND
Histology	0.62	ND
Performance status	0.66	ND
Time to progression for 1^st TKI therapy	0.09	0.06
Time to progression ≥18 months for 1^st TKI therapy	0.01	0.008
Time to progression for all lines of chemotherapy treatment before 2^nd TKI therapy	0.41	ND
Time interval between end of 1^st TKI therapy and start of afatinib or erlotinib	0.40	ND
Time interval between end of last chemotherapy treatment and start of afatinib or erlotinib	0.88	ND

Note: Only covariates found significant in univariate analysis (p < 0.1) were considered in multivariate analysis
Abbreviations: ND not done, TKI tyrosine-kinase inhibitor

ISSN: 1471-2407